James A. Bianco

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Fred Hutchinson Cancer Research Center is a non-profit organization which provides research and testing services. The company was founded in 1965 and is headquartered in Seattle, WA.

Veterans Administration Medical Center provides healthcare services. The private company is based in San Diego, CA.

ArtsFund is a platform that expands the capacity of the cultural sector by sharing resources, practices, and perspectives. The non-profit company is based in Seattle, WA, and has subsidiaries in the United States. It has a network of affiliated arts and cultural organizations in the central Puget Sound region. ArtsFund collaborates with the Department of Commerce to fund arts capital projects throughout the state, securing over $129 million for 262 capital projects. Since its founding in 1969, ArtsFund has distributed more than $100 million to over 650 arts organization grantees. The CEO of the company is Michael Romy Greer.

Rivkin Center for Ovarian Cancer is a non-profit organization that funds ovarian cancer research, screening, and educational programs for women. The company was founded by Saul E. Rivkin in 1996 and is headquartered in Seattle, WA.

Aequus BioPharma was formed in May 2007 as a majority-owned subsidiary of Cell Therapeutics, Inc. to discover, develop, and market biotherapeutics based upon the proprietary Genetic Polymer technology platform invented at CTI. Its technology addresses many of the traditional problems encountered during the development and commercialization of protein-based biopharmaceuticals. Aequus and CTI are collaborating on the development of AQB-101, a follow-on protein product or biosimilar based upon granulocyte-colony stimulating factor (G-CSF) coupled to a Genetic Polymer carrier domain. The company believe that AQB-101 provides an elegantly simple solution to the plasma half-life and bioavailability issues that have been observed with the original formulations of G-CSF-based biomedicines and which have been addressed by others using traditional chemical modification approaches in their G-CSF-based biosimilars.